The European Commission’s proposals for revising the EU pharmaceutical legislation will be “extremely damaging to the competitiveness of Europe’s industry and to our region’s strategic autonomy,” says Nathalie Moll, director general of the European pharmaceutical industry federation, EFPIA.
Whether the proposed legislation is “naivety, blind optimism or a more conscious decision to rely on innovation from the US...